Chembio Diagnostic Systems, Inc.
5
0
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
1 terminated/withdrawn out of 5 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Investigational Study to Evaluate the DPP® Syphilis Screen & Confirm Antibody Point-of-care Test (POCT) to Diagnose Infectious Syphilis
Role: collaborator
Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid
Role: lead
Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System
Role: lead
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Role: lead
Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population
Role: lead
All 5 trials loaded